2 min read
ASCO Annual Meeting
Meet Veristat at the 2025 ASCO Annual Meeting
Advancing Oncology Therapies for Patients in Need
Veristat is proud to...
2 min read
Latest Updates from FDA & EMA
April 2019 Updates
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) and European Medicines Agency (EMA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval. Below are the relevant links to updates provided in April 2019.
FDA Updates
FDA has Finalized the Following Draft Guidance Documents:
REMS: FDA’s Application of Statutory Factors in Determining When a REMS Is Necessary (Issued on 04Apr2019) https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM521504.pdf
Pediatric Information Incorporated Into Human Prescription Drug and Biological Product Labeling Guidance for Industry (Issued on 27Mar2019)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM341394.pdf
Pediatric HIV Infection: Drug Product Development for Treatment (Issued on 19Mar2019)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM607416.pdf
Human Immunodeficiency Virus-1 Infection: Developing Systemic Drug Products for Pre-Exposure Prophylaxis Guidance for Industry (Issued on 19Mar2019)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM610623.pdf
FDA has Issued the Following New Draft Guidance Documents:
Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biologics with Continuous Outcomes Guidance for Industry (Issued April 2019)
https://www.fda.gov/media/123801/download
Compliance Policy for Combination Product Postmarketing Safety Reporting (Issued April 2019)
https://www.fda.gov/media/111795/download
FDA In The News:
The Office of Management and Budget will begin enforcing the Congressional Review Act (CRA) of 1996. OMB intends to review all guidance that can be considered “major”.
- OMB’s New Reviews of FDA Guidance May Be a Boon for Biopharma Industry (Published on 15Apr2019)
https://www.raps.org/news-and-articles/news-articles/2019/4/ombs-new-reviews-of-fda-guidance-may-be-a-boon-fo - The Office of Management and Budget has issued a memo explaining a plan to enforce the Congressional Review Act (CRA) of 1996. (Published 11Apr2019) https://www.whitehouse.gov/wp-content/uploads/2019/04/M-19-14.pdf
Minimal Residual Disease as a Surrogate Endpoint for Product Development for Multiple Myeloma: Comparing FDA and EMA Guidances (Published on 08Apr2019)
Patient Groups, Industry Seek Changes to Rare Disease Drug Guidance (Published 04Apr2019)
Statement from FDA Commissioner Scott Gottlieb, M.D. and Deputy Commissioner Anna Abram on new 2019 efforts to improve the quality of compounded drugs (Published on 03Apr2019)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635182.htm
Statement by FDA Commissioner Scott Gottlieb, M.D., Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D. and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D. on Expanded Access –Looking Forward (Published on 29Mar2019)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634766.htm
CDER Reorganization to Go Live on March 31, 2019
EMA Updates
MHRA Offers No-Deal Guidance on Pharmaceutical Product Certificates (Published 08Apr2019)
1.7% increase of fees payable to EMA from 1 April 2019 (Published 01Apr2019)
https://www.ema.europa.eu/en/news/regulatory-information-17-increase-fees-1-april-2019
- Regulatory Affairs
- Regulatory Consulting
- Regulatory Approvals
- Agency Meetings Support
- Regulatory Publishing